Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Another notable valuation metric for EXEL is its P/B ratio of 4.54. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

so it seems like value investors will conclude that EXEL is the superior option right now. This article originally published on Zacks Investment Research (zacks.com).

EXEL has seen stronger estimate revision activity and sports more attractive valuation metrics than TECH, so it seems like value investors will conclude that EXEL is the superior option right now.

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of unresectable, locally advanced or metastatic pancreatic ...